| アブストラクト | BACKGROUND: Evidence on the drug effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on mortality in patients with diabetic kidney disease (DKD) remains limited. We analyzed patients with DKD newly prescribed SGLT2is using large-scale Asian real-world data. METHODS: We utilized commercially available databases provided by DeSC Healthcare, Inc., between 2014 and 2023. All-cause mortality was compared across five pairs of new users of SGLT2is-canagliflozin, empagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin-each versus dapagliflozin, using a target trial emulation framework with propensity score matching. RESULTS: Among 12,308 patients with DKD, 1,553 new users of canagliflozin, 2,948 of empagliflozin, 1,672 of ipragliflozin, 931 of luseogliflozin, and 955 of tofogliflozin were matched 1:1 with corresponding new users of dapagliflozin. The mean age of participants ranged from 72.2 to 75.4 years, and 67.4-72.2% were men. During a median follow-up period of 1.12-1.96 years, the incidence of all-cause mortality among new users of SGLT2 inhibitors ranged from 32.3 to 46.2 for dapagliflozin, and was 28.8 for canagliflozin, 38.8 for empagliflozin, 33.4 for ipragliflozin, 33.8 for luseogliflozin, and 25.7 for tofogliflozin, per 1,000 person-years. Both the cumulative incidence and hazard ratios for all-cause mortality were comparable among new users of each SGLT2i compared with dapagliflozin (all log-rank P > 0.05; 95% CIs included 1). CONCLUSIONS: Comparable effects of SGLT2is on all-cause mortality risk were observed in patients with DKD using the Asian real-world data. This apparent class effect on all-cause mortality suggests that different agents may confer comparable short-term mortality benefits when selected according to patient characteristics. |
|---|
| ジャーナル名 | Clinical and experimental nephrology |
|---|
| Pubmed追加日 | 2026/4/11 |
|---|
| 投稿者 | Nobayashi, Hiroki; Satoh, Michihiro; Hirose, Takuo; Nakayama, Shingo; Iwabe, Yutaro; Yagihashi, Takahito; Hashimoto, Hideaki; Murakami, Takahisa; Okada, Kouji; Mori, Takefumi; Metoki, Hirohito |
|---|
| 組織名 | Division of Public Health, Hygiene and Epidemiology, Faculty of Medicine, Tohoku;Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyagino-Ku, Sendai,;Miyagi, 983-8536, Japan.;Miyagi, 983-8536, Japan. satoh.mchr@tohoku-mpu.ac.jp.;Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital,;Sendai, Japan. satoh.mchr@tohoku-mpu.ac.jp.;Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank;Organization, Tohoku University, Sendai, Japan. satoh.mchr@tohoku-mpu.ac.jp.;Division of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and;Pharmaceutical University, Sendai, Japan.;Organization, Tohoku University, Sendai, Japan.;Sendai, Japan.;Division of Clinical Pharmaceutics and Pharmacy Practice, Faculty of;Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai,;Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41963737/ |
|---|
